Functional Endoscopic Sinus Surgery (FESS), Biologics, and Biomarkers: A Strategic Approach to Managing CRSwNP

Tuesday, October 1, 2024

8:00 AM – 9:00 AM EDT

Location: MBCC, Art Deco 229AB

CME/MOC Credit: 1

Disclosure(s):

Christine Blanche Franzese, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Cecelia C. Damask, DO:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Matthew W. W. Ryan, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

James W. Mims, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

PROGRAM DESCRIPTION: Chronic sinusitis with nasal polyposis is becoming more widely recognized as a Type 2 inflammatory disease but the best treatment strategies for personalized patient treatment and which biomarkers to use to predict treatment success are still being investigated. For some patients, a complete FESS followed by medical therapy is successful at controlling disease recurrence. For others, this is not the case, sometimes requiring numerous additional surgeries to control the burden of disease. With the advent of FDA approved biologics for nasal polyps and additional Phase three trials combining biologic use with surgery, there is the potential to use available biomarkers and patient characteristics to direct therapy to minimize the need for further additional surgery and corticosteroid use. This panel uses patient cases with biomakers, images, and videos, as well as currently available evidence and guidelines, to discuss different therapeutic approaches to treatment and ways to potentially answer the questions: Who will do well with just surgery and medicated rinses? Who will need adjuvant biologic therapy or would need that treatment first?

Learning Objectives:

Discuss the available phenotypic and endotypic biomarkers and their practical clinical application in decision-making for treatment of CRSsNP.
Describe the utilization of biologic therapies for CRSwNP alone, pre-, and post-FESS.
Discuss a guided, personalized treatment approach to CRSwNP using FESS, medical therapy, and biologics.

Moderator(s)

Christine Blanche Franzese, MD

Professor
University of Missouri-Columbia
Columbia, MO, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Panelist(s)

CD

Cecelia C. Damask, DO

DO
Orlando ENT and Allergy
Orlando, FL, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
Matthew W. W. Ryan, MD

Professor
UT Southwestern Medical Center
Dallas, TX, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
James W. Mims, MD

Professor
Wake Forest School of Medicine
Winston Salem, NC, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.